Thus RASopathy-associated switch III mutations do not show changes in nanoclustering, but may have unknown alterations (N-rasT50I, Figure 5 and [Cirstea et al., 2010]; K-rasV152G, Figure 6; K-ras-E153V and K-ras-F156L [Gremer et al., 2011; Mazhab-Jafari et al., 2015]). The gene discussed is KRAS; the disease is RASopathy.